Roche’s Analyst Event at ISTH 2017


Agenda:
HAVEN2: Ph3 interim data of emicizumab (ACE910) prophylaxis in pediatrics with hemophilia A with inhibitors; aspects of disease management and emicizumab global development program	Gallia Levy, M.D., Ph.D., Global Development Team Leader emicizumab
HAVEN1: Ph3 data of emicizumab (ACE910) prophylaxis in adults with hemophilia A with inhibitors	Prof. Dr. med. Johannes Oldenburg, University Clinic Bonn, Institute of Experimental Hematology and Transfusion Medicine
Welcome	Daniel O’Day, CEO Roche Pharmaceuticals

Please register to access the replay* *Privacy notice

First Name *

Last name *

Corporate Email *

Company Name *

confirm you are a human *

Investors

Downloads

PDF

PDF